<DOC>
	<DOCNO>NCT01376310</DOCNO>
	<brief_summary>This open-label study permit subject solid tumor leukemia , currently clinically benefit another GSK sponsor trial GSK1120212 either monotherapy combination continue access GSK1120212 .</brief_summary>
	<brief_title>GSK1120212 Rollover Study</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Has provide sign informed consent study . 2 . Has demonstrate compliance parent study study treatment ( ) , treatment visit schedule , requirement restriction list consent form . 3 . Is currently participate GSK1120212 study receive treatment GSK1120212 . 4 . Is currently receive clinical benefit determine investigator previous treatment GSK1120212 either monotherapy part combination treatment regimen . 5 . Continued ability swallow retain orally administer study treatment ( ) clinically significant GI abnormality may alter absorption malabsorption syndrome major resection stomach bowel . 6 . Female subject childbearing potential , defined parent study , must willing continue practice acceptable method contraception use parent study rollover study least 4 month last dose GSK1120212 . 7 . Female subject childbearing potential , defined parent study , must negative serum pregnancy test time transition study . 8 . Subjects enrol France : In France , subject eligible inclusion study either affiliate beneficiary social security category . 1 . Permanent discontinuation GSK1120212 parent study due toxicity disease progression . 2 . Current use prohibitive medication ( ) list Section 6.2 . NOTE : Use anticoagulant warfarin permit ; however , international normalization ratio ( INR ) must monitor accordance local institutional practice . 3 . Any unresolved toxicity meet study treatment discontinuation study withdrawal criterion parent study time transition study . 4 . Bazettcorrected QT ( QTcB ) interval â‰¥501 msec time transition study 5 . Left ventricular ejection fraction ( LVEF ) &lt; institutional low limit normal ( LLN ) ECHO ( prefer ) MUGA scan time transition study . 6 . Nursing female . 7 . Any serious and/or unstable preexist medical , psychiatric disorder condition time transition study could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>